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Overexpression of mutated IB inhibits vascular
smooth muscle cell proliferation and intimal
hyperplasia formation
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Bradley S. Taylor, MD, and Edith Tzeng, MD, Pittsburgh, Pa
Purpose: Vascular injury and inflammation are associated with elaboration of a number of cytokines that signal through
multiple pathways to act as smooth muscle cell (SMC) mitogens. Activation of the nuclear factor–kappa B (NF-B)
transcription factor is essential for SMC proliferation in vitro and is activated by vascular injury in vivo. Activation of
NF-B is controlled by several upstream regulators, including the inhibitors of kappa B (IB). These proteins bind to and
keep NF-B inactivated. The purpose of this study was to determine whether adenoviral gene transfer of a mutated IB
super-repressor (AdIBSR) could inhibit development of intimal hyperplasia in vivo and to investigate how over-
expression of this construct influences in vitro SMC proliferation and cell cycle regulatory proteins.
Methods: A rat carotid injury model was used to study prevention of intimal hyperplasia. Arteries were assayed 14 days
after injury and infection with AdIBSR or adenoviral-galactosidase (AdLacZ). Untreated SMC or SMC infected with
AdLacZ or AdIBSR were stimulated with 10% fetal bovine serum, interleukin-1, or tumor necrosis factor-.
Electrophoretic mobility shift assays were used to assay for NF-B activation. Protein levels of IB and cyclin-dependent
kinase inhibitors p21Cip1/Waf1 and p27Kip1 were determined with Western blot analysis. Proliferation was measured with
3H-thymidine incorporation assays.
Results: AdIBSR inhibited the development of intimal hyperplasia by 49% (P < .05). Infection with AdIBSR
significantly suppressed in vitro SMC proliferation when stimulated with serum, interleukin 1, or tumor necrosis factor
, and did not result in cell death. Inhibition of proliferation was associated with increased p21Cip1/Waf1 and p27Kip1
protein levels.
Conclusions: Gene transfer of IB super-repressor inhibited development of intimal hyperplasia in vivo and SMC
proliferation in vitro. The antiproliferative activity may be related to cell cycle arrest through upregulation of the
cyclin-dependent kinase inhibitors p21 and p27. Overexpression of IBmay be a future therapeutic option in treatment
of vascular diseases. (J Vasc Surg 2003;38:812-9.)
Vascular injury characterized by endothelial disruption
and dysfunction is a common pathophysiologic feature in a
number of vascular diseases, including atherosclerosis,
post-angioplasty stenosis or in-stent stenosis, and bypass
graft failure. Elaboration of multiple cytokines and growth
factors from cells native to the vessel wall and from infiltrat-
ing leukocytes and platelets creates a local inflammatory
environment. These stimuli promote vascular smooth mus-
cle cell (SMC) proliferation and migration, which can lead
to development of hemodynamically significant intimal
hyperplasia.
Mitogenic stimuli that promote SMC proliferation
function through multiple intracellular signaling pathways.
These proliferative signals involve a complex network of cell
surface receptors, small guanosine triphosphatases, and
mitogen-activated protein kinases. In addition, many of
these stimuli activate the nuclear factor–kappa B (NF-B)
family of transcription factors. The NF-B transcription
factors are composed of dimers of members of the Rel
family of proteins that includes p50, p52, p65, c-Rel, and
RelB. When inactivated, these dimers remain in the cytosol,
complexed with another group of proteins termed inhibi-
tors of kappa B (IB). When stimulated, signaling through
the upstream kinases, NF-B–inducing kinase and IB
kinases (IKK), leads to phosphorylation of IB. This critical
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phosphorylation of IB leads to its ubiquitination and
subsequent degradation. The release of NF-B from IB
binding results in nuclear translocation of NF-B and tran-
scriptional activation of myriad genes.1,2
Signal transduction involving the NF-B pathways is
common to many cell types in response to inflammatory
stimuli. Activation of NF-B is involved in SMC prolifera-
tion both in vitro and in vivo. Expression of NF-B is
essential for proliferation of cultured SMCs.3 In vivo,
NF-B is present in the nuclei of SMCs in the fibrotic
thickened areas of atherosclerotic lesions, but not in SMCs
of normal blood vessels.4 Activation of NF-B also occurs
after balloon injury of arteries in rat models.5,6
SMC proliferation can be regulated by NF-B. Both
pharmacologic and gene transfer strategies have been used
to target inhibition of NF-B. Antioxidants that inhibit
NF-B activation have been used to prevent serum-
stimulated and thrombin-stimulated SMC proliferation.3,7
Over-expression of IB8,9 or dominant-negative mutants
of IKK10 inhibit SMC proliferation induced by various
stimuli. Likewise, double-stranded decoy oligonucleotides
that bind NF-B and keep it localized and inactivated in the
cytosol decrease SMC proliferation in vitro.3 Antisense
oligonucleotides that decrease p65 synthesis have been
used to inhibit cultured SMC proliferation11 and intimal
hyperplasia formation after angioplasty injury in rats.12
Although inhibition of NF-B decreases SMC prolifera-
tion, little is known about how this inhibition influences the
cell cycle and cell cycle regulatory proteins.
In this study we used an adenoviral construct of IB
that has been mutated at serines 32 and 36. These muta-
tions prevent IB phosphorylation, keeping NF-B in its
inactivated cytosolic location complexed with IB. We used
an adenoviral vector because of the high transfection effi-
ciencies and subsequent high levels of transgene expression.
The purpose of the present study was to determine the
effect of adenoviral delivery of this IB super-repressor
(AdIBSR) on development of intimal hyperplasia in an
in vivo rat carotid artery injury model and to determine how
over-expression of this IB construct influences in vitro
SMC proliferation and cell cycle regulatory proteins.
METHODS
Cell culture. Aortic vascular SMCs were cultured
from explanted thoracic aortas, as described,13 from
Sprague-Dawley rats (Harlan, Indianapolis, Ind). Cultured
cells had the characteristic hill-and-valley appearance and
were routinely more than 95% pure at SMC -actin stain-
ing. Cells were grown in Dulbelcco modified Eagle me-
dium (low glucose)/Ham’s F12 (1:1, vol-vol) (JRH, Le-
nexa, Kan) supplemented with 10% fetal bovine serum
(FBS), 100 U/mL of penicillin, 100 g/mL of streptomy-
cin, and 4 mmol/L of L-glutamine, and were maintained in
a 37°C, 95% air/5% carbon dioxide incubator.
Adenovirus generation and propagation. An E1-
deleted and E3-deleted adenoviral vector carrying the IB
complementary DNA mutated at serines 32 and 36
(AdIBSR; generous gift of David Brenner, Chapel Hill,
NC) was designed and constructed as described.14 The
serines at these positions were mutated to alanines, which
cannot be phosphorylated. The titer of AdIBSR was
approximately 2  1010 plaque-forming units (PFU) per
milliliter, and the adenoviral -galactosidase gene (Ad-
LacZ) was approximately 1011 PFU/mL.
Adenoviral infection of SMC in vitro. SMCs (pas-
sages 2-6) were plated for 24 hours, and then were serum-
starved for an additional 24 hours to induce cell cycle arrest.
The SMCs were then infected for 4 hours at 37°C with
AdLacZ or AdIBSR with a multiplicity of infection
(MOI) of 100 PFU per cell. This MOI was chosen on the
basis of previous experiments in which infection efficiency
greater than 70% was determined. Immediately after infec-
tion, cells were starved for an additional 24 hours. Interleu-
kin 1beta (IL-1; 1 ng/mL) or tumor necrosis factor 
(TNF-; 1 ng/mL) was added to some of the groups when
stimulated.
Cellular proliferation. Growth-arrested SMC were
stimulated to proliferate in the presence of 5 Ci/mL of
3H-thymidine (New England Nuclear, Boston, Mass) for
24 hours. For some experiments cells were treated with
IL-1 (1 ng/mL) or TNF- (1 ng/mL). 3H-thymidine
incorporation into trichloroacetic acid–precipitated DNA
was quantified with scintillation counting.
Western blot analysis. SMC were collected after 24
hours of exposure to the various treatment groups by
scraping in 20 mmol/L of Tris with 100 mol/L of
phenylmethylsulfonylfluoride (Sigma, St Louis, Mo), 1
mol/L of leupeptin (Sigma), and 1 mol/L sodium of
orthovanadate (Sigma). Protein was quantified with bicin-
choninic acid protein assay (Pierce, Rockford, Ill). Whole
cell samples (30 g) were subjected to sodium dodecylsul-
fate polyacrylamide gel electrophoresis on 10% and 13%
gels and transferred to nitrocellulose membranes (Schlei-
cher & Schuell, Keene, NH) as described.13 Membranes
were blocked in 5% nonfat milk for 2 hours, and hybridized
with IB, p21, and p27 (Santa Cruz Biotechnology, Santa
Cruz, Calif) followed by horseradish peroxidase–linked
goat anti-rabbit or goat anti-mouse (1:10,000; Pierce).
Proteins were visualized with chemiluminescent reagents
according to the manufacturer’s instructions (Supersignal
Substrate; Pierce).
Electrophoretic mobility shift assay. Nuclear pro-
teins were extracted and quantified as described.15 Double-
stranded consensus oligonucleotides with the NF-B motif
5-GATCGAGGGGA-CTTTCCCTAAAAGC-3 (Strat-
agene, La Jolla, CA) were incubated with [-32P]-
adenosine triphosphate (New England Nuclear). The reac-
tion was catalyzed with T4 kinase and incubated in 10-
kinase buffer at 37°C for 30 minutes. Labeled
oligonucleotide was column-purified on Sephadex G-25
columns (Amersham Pharmacia Biotech, Arlington
Heights, Ill). Radioactivity was assayed with scintillation
counting. Five micrograms of nuclear protein was incu-
bated with labeled oligonucleotides (approximately
150,000 cpm) in binding buffer for 30 minutes at 37°C.
Specificity of binding was ascertained with cold competi-
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tion with an excess of unlabeled NF-B oligonucleotides.
Protein-DNA complexes were separated from free DNA
probe with electrophoresis with 5% polyacrylamide gel.
Gels were dried under vacuum on Whatman paper in a gel
dryer (Bio-Rad Laboratories, Hercules, Calif) and were
exposed to autoradiographic film and phosphor-imaging.
Flow cytometry. Cells were gently scraped and
washed in phosphate buffered saline solution (PBS). SMC
apoptosis was assessed by monitoring inversion of phospha-
tidylserine to the outer leaf of the plasma membrane with
annexin-V–fluorescein isothiocyanate and propidium io-
dide staining, performed according to the manufacturer’s
instructions. Flow cytometer analysis was performed on a
FACSort (Becton Dickinson; Franklin Lakes, NJ). Total
cell population consisted of SMCs that were annexin-V
single positive (apoptotic), propidium iodide single positive
(necrotic), annexin-V and propidium iodide double posi-
tive (“apo-necrotic”), and annexin-V and propidium iodide
double negative (live).
Viability. Trypan blue exclusion was analyzed by
trypsinizing (0.25%; Gibco, Grand Island, NY) the cells and
diluting 1:4 with trypan blue (Gibco) to determine whether
AdIBSR was cytotoxic to SMC. Both adherent and
floating cells were collected. Cells were counted on a he-
mocytometer, and percentage viability was calculated by
dividing number of cells excluding trypan blue by total
number of cells.
Cytokine measurement. Cell culture supernatants
were collected for determination of rat IL-6 levels with
Quantikine enzyme-linked immunosorbent assay (R&D
systems, Minneapolis, Minn) according to the manufactur-
er’s instructions.
Animal injury. All animal procedures were performed
with aseptic techniques in accordance with the Institutional
Animal Care and Use Committee of the University of
Pittsburgh. Adult male Sprague-Dawley rats weighing 400
to 450 gm were anesthetized with intraperitoneal sodium
pentobarbital (Nembutal, 45 mg/kg; Abbott Laboratories,
North Chicago, Ill) and supplemental inhalational isoflu-
rane. The left carotid artery was injured as described.16 In
brief, a midline neck incision was used to gain access to the
left common carotid artery, internal carotid artery, and
external carotid artery. Vascular control was obtained with
noncrushing vascular clamps (FST), and a 2F embolectomy
catheter (Baxter, Chicago, IL) was inserted through an
arteriotomy in the external carotid artery. The balloon was
inflated to 5 atmospheres of pressure for 5 minutes. The
catheter was removed, and approximately 200 L of a viral
solution of AdLacZ or AdIBSR (1 108 PFU/mL) was
instilled into the carotid artery over 30 minutes. After the
incubation period, the arteries were flushed, the external
carotid artery was ligated, and return of flow was ensured in
the common and internal carotid arteries. Animals were
killed on days 3 or 14 after injury.
Tissue processing and analysis. Rat carotid arteries
were perfused and fixed in situ with PBS and 2% parafor-
maldehyde. Vessels were fixed for 2 hours in 2% parafor-
maldehyde and then cryoprotected overnight in 30% su-
crose at 4°C. Vessels were then frozen in 2-methylbutane.
Seven-micrometer-thick sections were cut at equally spaced
intervals along the length of the vessels. Sections were then
stained with hematoxylin-eosin. The center of the injury
was identified, and luminal, intimal, medial, and total vessel
areas were measured in 10 sections, each spaced approxi-
mately 200 m apart within the region of the injury.
Images were obtained with an Olympus Provis microscope
(Olympus, Tokyo, Japan), and areas were using Scion
image.
Proliferating cell nuclear antigen immunohisto-
chemistry. Rat carotid arteries were injured as described,
and the animals were killed on day 3 after injury. Immuno-
staining for proliferating cell nuclear antigen (PCNA) was
performed. Mouse monoclonal anti-PCNA antibody (1:
50; Sigma) followed by biotinylated secondary antibody
were used. Slides were treated with an avidin-biotin block,
exposed to DAB black with a nuclear counterstain, and
analyzed with light microscopy. Data are represented as
PCNA labeling index, which is percentage of total cells
within a given area positive for PCNA.
Statistical analysis. Results are expressed as mean 	
SEM. Differences among groups were analyzed with one-
way analysis of variance with the Student-Newman-Keuls
post hoc test for all pairwise comparisons (SigmaStat; SPSS,
Chicago, Ill). Statistical significance was assumed at P 

.05.
RESULTS
Expression of IBSR by adenoviral vector. SMC
were infected with either AdLacZ (MOI 100) or
AdIBSR (MOI 10 and 100) for 4 hours, serum-starved
for 20 hours, then grown in 10% FBS for 24 hours. Lysates
were collected and analyzed for IBSR transgene expres-
sion with Western blot analysis. The tagged transgene
product can be visualized slightly larger than the native
IB. A MOI-dependent increase in IBSR expression
can be seen in the AdIBSR-infected SMCs (Fig 1, A).
Protein levels of IBSR are significantly higher than native
IB levels in the AdIBSR (MOI 100)–infected SMCs.
This MOI was used in the remainder of the experiments.
IBSR gene transfer decreased activation of NF-
B. The function of AdIBSR in blocking NF-B bind-
ing was assessed with electrophoretic mobility shift assay
(EMSA). Untreated SMCs and SMCs treated with either
AdLacZ or AdIBSR were serum-starved for 48 hours.
Cultures were then either serum-stimulated or stimulated
with IL-1 (1 ng/mL) or TNF- (1 ng/mL). Nuclear
extracts were collected 90 minutes after stimulation. This
time point was used on the basis of previous experiments
that demonstrated maximal NF-B binding in SMCs, as
assayed with EMSA (data not shown). Gene transfer of
IBSR demonstrates near complete (10-fold less; P 

.01) inhibition of NF-B binding in all treatment groups
compared with gene transfer of LacZ (Fig 1, B). These
experiments demonstrate that adenoviral gene transfer of
IBSR (MOI 100) results in functional transgene expres-
sion that effectively inhibits NF-B activation.
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AdIBSR inhibited intimal hyperplasia formation
after balloon injury. Sprague-Dawley rats were subjected
to balloon injury as described above. After injury, carotid
arteries were infected with viral solutions (1  108 PFU/
mL) of AdIBSR or AdLacZ. Transfection efficiency with
this intra-arterial titer was approximately 20% assayed with
X-gal staining (data not shown). Arteries were harvested 14
days after injury and intima-media ratios were compared.
Intimal hyperplasia was suppressed by 49%	 7% in animals
treated with AdIBSR compared with AdLacZ-treated
animals (n 10; P
 .05) (Fig 2). There was no significant
change in medial areas between the two groups. Likewise,
there was no significant difference in total area of the
arteries from either group, which suggests that at this time
point there was no compensatory arterial dilatation. This is
consistent with the finding that carotid luminal area was
149%	 6% greater in AdIBSR-treated vessels compared
with AdLacZ-treated control vessels 14 days after injury (P

 .05).
To examine the effects of IBSR gene transfer on
intravascular proliferation after balloon injury, PCNA stain-
ing was performed on the carotid arteries 3 days after injury.
At this time there was no significant neointima formation.
The percentage of total cells staining positive for PCNA per
area was 1.7%	 0.4% in AdLacZ-treated vessels, compared
with 0.4%	 0.14% in AdIBSR-treated vessels (P 
 .05)
(Fig 3).
IBSR gene transfer decreased TNF--stimulated
IL-6 production. The effects of mutated IB gene
transfer on the inflammatory response of SMC was investi-
gated. Twenty-four hours after adenoviral infection, SMCs
were treated with TNF- (10 ng/mL). Cell culture super-
natants were collected after 24 hours, and IL-6 level was
quantified. IB gene transfer decreased IL-6 levels by 72%
compared with LacZ controls (P 
 .05) (Fig 4). These
results suggest an anti-inflammatory effect secondary to
inhibition of NF-B activation and are consistent with
previous studies.8,9
AdIBSR suppressed SMC proliferation in
vitro. Untreated SMCs and SMCs treated with either Ad-
LacZ or AdIBSR were serum-starved for 48 hours. Cells
were then stimulated with media containing serum (10%
FBS), IL-1 (1 ng/mL), or TNF- (1 ng/mL) for 24
hours in the presence of 3H-thymidine (5 Ci/mL).
AdIBSR infection inhibited DNA synthesis in serum-
stimulated SMC to levels 42.5% 	 9.2% (P 
 .01) those of
uninfected control SMC. Likewise, AdIBSR treatment
significantly suppressed DNA synthesis in IL-1-stimu-
lated and TNF--stimulated SMCs compared with both
uninfected and AdLacZ-treated control SMCs. 3H-thymi-
dine uptake in AdIBSR-infected SMCs was reduced to
50.2% 	 1.9% (P 
 .05) and 28.2% 	 6.7% (P 
 .01) that
in uninfected IL-1–stimulated and TNF-stimulated control
SMCs (Fig 5). Results are cumulative from three indepen-
dent experiments, with each condition assayed in triplicate.
Infection with AdIBSR did not influence cell
viability or apoptosis. Cell viability was evaluated 24
hours after AdIBSR infection to determine whether
IBSR expression is toxic to SMC. With trypan blue
exclusion, SMCs were more than 90% viable when in-
fected with AdLacZ or AdIBSR (Fig 6, A). In addi-
tion, AdLacZ-treated or AdIBSR-treated SMC were
assessed for apoptosis 24 hours after stimulation with
serum alone or with TNF- (1 ng/mL). Relative per-
centages of viability and apoptotic or necrotic SMCs
were determined with fluorescent-activated cell sorting
of cells stained with annexin-V and propidium iodide.
AdIBSR infection had no significant influence on the
viability profile of serum-stimulated or TNF--stimu-
lated SMC populations compared with both nontrans-
fected and AdLacZ-infected control SMCs (Fig 6, B).
These data suggest that AdIBSR infection does not
influence SMC proliferation by causing cell death. Both
of these results are representative of three independent
experiments.
Fig 1. Expression and function of AdIBSR. A, Western blot
analysis of IB protein levels in noninfected smooth muscle cells
(SMCs) and SMCs infected with adenoviral -galactosidase gene
(AdLacZ; multiplicities of infection [MOI], 100) or AdIBSR
(MOI, 10 and 100) show no change in expression of native IB
but a MOI-dependent increase in IBSR transgene expression.
B, Electrophoretic mobility shift assay for NF-B. Untreated SMC
or SMC infected with AdLacZ or AdIBSR (MOI, 100) were
stimulated with media containing 10% fetal bovine serum (FBS),
interleukin-1 (IL-1;, 1 ng/mL), or tumor necrosis factor– 
(TNF-, 1 ng/mL) for 90 minutes. AdIBSR infection signifi-
cantly decreases binding (10-fold reduction; P 
 .01) of nuclear
protein to labeled NF-B oligonucleotides. Incubation with exces-
sive cold probe (C.P.) decreases binding noted with uninfected
serum-stimulated SMCs. Results are representative of three inde-
pendent experiments.
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Gene transfer of IBSR increased cyclin-dependent
kinase inhibitors p21Cip1/Waf1 and p27Kip1. p21Cip1/
Waf1 levels were low in serum-starved SMCs. Serum stimu-
lation for 24 hours led to a small increase in p21Cip1/Waf1
expression. AdLacZ-infected SMCs showed no difference
from uninfected serum-stimulated control SMCs at both
12 and 24 hours. However, AdIBSR infection dramati-
Fig 2. Inhibition of intimal hyperplasia 14 days after balloon injury. Representative cross sections from arteries treated
with AdLacZ (A) or AdIBSR (B). Each artery was treated with approximately 200 L of viral solution containing 1
 108 PFU/mL. C, Arteries from animals treated with AdIBSR had a 49% 	 7% reduction (n  10 rats per group;
P 
 .05) in intima-media ratio. AdIBSR infection resulted mainly in decrease in intimal areas (D), with little
influence on medial areas (E).
Fig 3. Inhibition of proliferating cell nuclear antigen (PCNA)
staining 3 days after balloon injury. AdIBSR decreased the
percentage of total cells positive for PCNA staining per given area
of carotid (PCNA LI) by 76% 	 8% compared with AdLacZ
control vessels (n  5 rats; 10 high power fields per carotid artery;
P 
 .05).
Fig 4. AdIBSR significantly decreased tumor necrosis factor 
(TNF-)–induced smooth muscle cell (SMC) interleukin 6 (IL-6)
production. SMC were stimulated with TNF- (10 ng/mL) 24
hours after gene transfer, and cell culture supernatant IL-6 levels
were determined 24 hours after stimulation. IB gene transfer
decreased IL-6 levels by 72% compared with AdLacZ-treated SMC
(P 
 .05).
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cally increased p21Cip1/Waf1 protein levels after 12 and 24
hours of serum stimulation. In contrast, p27Kip1 protein
levels were high in quiescent cells, and did not change after
serum stimulation. Similar to with p21Cip1/Waf1, AdLacZ
infection did not influence p27Kip1 protein expression,
whereas overexpression of IBSR increased protein levels
at both 12 and 24 hours (Fig 7). AdIBSR did not
significantly influence protein levels of the cyclin-depen-
dent kinase inhibitor p16Ink4 (data not shown).
DISCUSSION
In the present study we demonstrated that overexpres-
sion of a mutant of IB that cannot be phosphorylated or
degraded, IBSR, suppressed injury-induced intimal hy-
perplasia formation in rats in vivo and significantly inhibited
serum-stimulated and cytokine-stimulated SMC prolifera-
tion in vitro. Overexpression of IB effectively inhibited
NF-B activation, and its antiproliferative activity may be
related to cell cycle arrest through upregulation of the
cyclin-dependent kinase inhibitors p21 and p27. Finally,
overexpression of IBSR did not increase cellular necrosis
or apoptosis, indicating that its in vitro effects on cell
number are predominantly through inhibition of SMC
proliferation.
In this study IB gene delivery was used to prevent
intimal hyperplasia in vivo. In vivo activation of the tran-
scription factor NF-B in SMC has been demonstrated in
both atherosclerotic lesions4,17 and injured blood ves-
sels.5,6 In addition to NF-B activation, Landry et al5
showed reduction in IB protein levels in blood vessels
after balloon injury, implicating a direct role for this system
in development of intimal hyperplasia. One previous
study12 inhibited NF-B activation with the goal of pre-
venting intimal hyperplasia formation. This study used
continuous periadventitial infusion (50 g/d) of antisense
oligonucleotides to the p65 subunit of NF-B and inhib-
ited neointima formation by 70%. The same study demon-
strated that antisense oligonucleotides to the p50 subunit
did not influence proliferation in vitro.12 Gene therapy
using IBSR may be more effective at blocking NF-B
activation than antisense oligonucleotides to p65, because
IBSR can bind NF-B hetero-dimers and homo-dimers
of multiple Rel family proteins.1,2 The significance of non-
specifically blocking nuclear translocation and activation of
NF-B dimers has yet to be determined, and is an impor-
tant consideration because different dimers of NF-B may
be either proinflammatory or anti-inflammatory.18 The
precise actions of the different dimers may depend on the
local cellular environment and the specific cell type. Strat-
egies that use pharmacologic agents or gene transfer of
other regulatory proteins, eg, IKK,10 could have similar
effects.
The choice of vector for gene transfer is also an impor-
tant consideration. Our studies used an adenoviral vector,
which has the advantage of high transfection efficiencies
and the ability to infect nonproliferating cells.19 The dura-
tion of transgene expression in most studies has been
limited from days to weeks. Other vectors such as adeno-
associated virus or retrovirus should demonstrate greater
duration of transgene expression, but are associated with
lower transfection efficiencies.19 These vectors, particularly
adenoviruses, may be limited in clinical settings by the
immune response. Adenoviral vectors may contribute to
local inflammation, which could experimentally be con-
trolled for by using saline solution–treated controls. How-
ever, rats used in these experiments should have limited
exposure to adenovirus, and their response may not reflect
how other species with previous exposure would respond.
Optimal vectors and gene transfer strategies for the treat-
ment of intimal hyperplasia are yet to be determined.
Our in vitro findings corroborate those of previous
studies that showed that activation of NF-B is a central
event in the proliferative response of SMC to serum, IL-1,
and TNF-. In bovine SMC, NF-B activation was essen-
tial but not sufficient to stimulate mitogenesis.3,7 Specifi-
cally, gene transfer of IB has been used to regulate
TNF- and fibroblast growth factor–induced SMC prolif-
eration.8,20
The critical role of NF-B in vascular injury can be
stressed in that multiple mitogens induce activation of
NF-B, and in turn NF-B can upregulate multiple inflam-
matory genes and SMC mitogens, including IL-6, platelet-
derived growth factor, IL-8, inducible nitric oxide syn-
thase. and both IL-1 and TNF-. The cytokine milieu
Fig 5. AdIBSR significantly decreases DNA synthesis in serum-
stimulated and cytokine-stimulated smooth muscle cells (SMCs).
SMCs were stimulated with media containing 10% fetal bovine
serum (FBS), interleukin 1 (IL-1, 1 ng/mL), or tumor necrosis
factor  (TNF-, 1 ng/mL) for 24 hours in the presence of
3H-thymidine (5 Ci/mL). In all treatment groups AdIBSR
infection (multiplicities of infection, 100) significantly decreased
DNA synthesis compared with uninfected and AdLacZ-treated
SMCs. AdIBSR infection inhibited DNA synthesis in serum-
stimulated SMCs to levels of 42.5% 	 9.2% (P 
 .01, *) that of
uninfected control SMCs. Likewise, AdIBSR treatment signifi-
cantly suppressed DNA synthesis in IL-1–stimulated and TNF-
–stimulated SMCs. 3H-thymidine uptake in AdIBSR-infected
SMCs was reduced to 50.2% 	 1.9% (P 
 .05, #) and 28.2% 	
6.7% (P 
 .01, *) that of uninfected IL-1–stimulated and TNF-
stimulated control SMCs. Results are cumulative from three inde-
pendent experiments, with each condition assayed in triplicate.
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that exists in the local environment of vascular injury will
ultimately determine the fate of NF-B signaling. Thus the
effects of IBSR gene transfer on intimal hyperplasia may
be through inhibition of local vascular inflammation and
elaboration of SMC mitogens.
In our study, AdIBSR treatment inhibited SMC
proliferation but did not significantly alter cell viability or
apoptosis. In our experiments, a relatively low experimental
dose of TNF- (1 ng/mL) was used, and proliferation and
apoptosis were assayed at relatively early time points. Obara
et al21 reported that adenoviral gene transfer of IB
induced TNF-–dependent apoptosis in human SMC.
Similar results have been demonstrated in other cell types.
In a study by Erl et al,22 the influence of IB gene transfer
on cell death in vitro was dependent on plating density. Our
data demonstrates a decrease in PCNA-positive cells at day
3. Inhibition of intimal hyperplasia by overexpression of
IBSR in vivo may be due to both inhibition of prolifer-
ation and induction of apoptosis, the ultimate pathways
depending on the microenvironment and the cytokine
milieu to which a cell is exposed.
Although this study and others demonstrate that gene
transfer of IB suppresses NF-B activation and inhibits
SMC proliferation, little is known about the signaling
pathways involved in this inhibition of proliferation. Our
data showed increases in p21Cip1/Waf1 and p27Kip1 protein
levels in serum-stimulated SMC after AdIBSR infection,
suggesting a direct effect on the cell cycle by inhibiting
NF-B. Marra et al23 similarly reported that salicylate in-
hibited NF-B activation and upregulated p21Cip1/Waf1
and p27Kip1 protein levels in human SMC stimulated by
platelet-derived growth factor. Again, these effects on pro-
liferation and cell cycle regulatory proteins may be second-
ary to reduced inflammatory response, with decreased pro-
duction of SMC mitogens. Further evaluation of the effect
of IBSR gene therapy on the cell cycle and other signal-
Fig 6. Infection with AdIBSR did not increase smooth muscle cell (SMC) apoptosis or necrosis. A, Influence of
treatment with AdLacZ or AdIBSR (multiplicities of infection, 100) on cell viability was assayed with trypan blue
exclusion at 24 hours after infection. There were no differences between untreated and infected SMCs, and all groups
had viable cell populations around 90%. Results are cumulative from three independent experiments performed in
duplicate. B, Apoptosis and necrosis were measured by staining SMCs with propidium iodide (PI) and annexin-V–
fluorescein isothiocyanate and measuring uptake with flow cytometry. Untreated and infected SMCs were serum-
starved for 48 hours and then stimulated with media containing 10% fetal bovine serum (FBS) alone or with tumor
necrosis factor– (TNF-, 1 ng/mL) for 24 hours. AdLacZ or AdIBSR infection did not significantly influence live
(annexin-V and PI double negative), apoptotic (annexin-V positive; PI negative), necrotic (annexin-V negative; PI
positive), or “apo-necrotic” (annexin-V and PI double positive) cell populations in 10% FBS-stimulated (a) or
TNF-–stimulated (b) SMCs. Results are representative of three independent experiments.
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ing pathways will be necessary before such therapy can be
safely applied in vascular disease in human beings.
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Fig 7. Treatment with AdIBSR increased protein levels of
p21Cip1/Waf1 and p27Kip1 in serum-stimulated smooth muscle cells
(SMCs). Untreated and adenoviral -galactosidase gene (Ad-
LacZ;) or AdIBSR (multiplicities of infection, 100) infected
SMCs were serum-stimulated for 12 or 24 hours. Cell lysates were
collected, and protein levels for cyclin-dependent kinase inhibitors
p21Cip1/Waf1 and p27Kip1 were determined with Western blot
analysis. Protein levels of p21Cip1/Waf1 were low in serum-starved
(SS) SMCs, slightly increased in uninfected and AdLacZ-infected
SMC, and significantly increased (P 
 .05) in AdIBSR-infected
cells at both 12 and 24 hours. Protein levels of p27Kip1 were similar
in SS, uninfected, and AdLacZ-treated SMCs. Comparable to the
effects on p21Cip1/Waf1, AdIBSR treatment significantly in-
creased p27Kip1 protein levels at both 12 and 24 hours (P 
 .05).
Results are representative of three independent experiments.
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